Market Overview

Exicure, Inc. Announces Expected Closing of Approximately $22 Million Private Placement Offering


Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and
immunotherapeutic drugs utilizing three-dimensional, spherical nucleic
acid (SNA™) constructs, announced today it expects to close a private
placement offering of its common stock at a per share price of $4.50 and
aggregate gross proceeds of approximately $22 million before fees and
expenses. The private placement is expected to close on or about August
22, 2018 subject to customary closing conditions.

Investors in the transaction include Sphera Global Healthcare, Knoll
Capital Management, an affiliate of Broadfin Capital, LLC and Sio
Capital Management LLC among other healthcare dedicated investors.

Exicure expects to use the proceeds from this offering for working
capital and general corporate purposes, which include advancing the
development of Exicure's drug candidates, including the advancement of
AST-008, an SNA consisting of toll-like receptor 9, or TLR9 agonists,
designed for immuno-oncology applications, as well as XCUR17, an
antisense SNA that targets the mRNA encoding IL-17RA, a protein that is
considered essential in the initiation and maintenance of psoriasis.

The offer and sale of the foregoing securities was made in a transaction
not involving a public offering and the securities have not been
registered under the Securities Act of 1933, as amended (the "Securities
Act"), or applicable state securities laws. Accordingly, the securities
may not be reoffered or resold in the United States except pursuant to
an effective registration statement or an applicable exemption from the
registration requirements of the Securities Act and such applicable
state securities laws. As part of the transaction, the Company has
agreed to file a registration statement with the Securities and Exchange
Commission for purposes of registering the shares of common stock issued
in the private placement.

This press release does not constitute an offer to sell or the
solicitation of an offer to buy the securities, nor shall there be any
sale of the securities in any state in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification under
the securities laws of such state. Any offering of the securities under
the resale registration statement will only be by means of a prospectus.

Ladenburg Thalmann, Castle Hill Capital Partners and Katalyst
Securities, LLC served as placement agents for the transaction. The
Company was advised by Sidley Austin LLP and Ladenburg Thalmann was
advised by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

About Exicure, Inc.

Exicure, Inc. is a clinical stage biotechnology company developing a new
class of immunomodulatory and gene regulating drugs against validated
targets. Exicure's proprietary 3-dimensional, spherical nucleic acid
spherical nucleic acid (SNA™) architecture is designed to unlock the
potential of therapeutic oligonucleotides in a wide range of cells and
tissues. Exicure's lead programs address inflammatory diseases, genetic
disorders and oncology. Exicure is based outside of Chicago, IL.

Forward Looking Statements

This press release contains forward-looking statements (including within
the meaning of Section 21E of the United States Securities Exchange Act
of 1934, as amended, and Section 27A of the United States Securities Act
of 1933, as amended) concerning the Company the Company's technology,
potential therapies and other matters. Forward-looking statements
generally include statements that are predictive in nature and depend
upon or refer to future events or conditions, and include words such as
"may," "will," "should," "would," "expect," "plan," "believe," "intend,"
"look forward," and other similar expressions among others. Statements
that are not historical facts are forward-looking statements.
Forward-looking statements are based on current beliefs and assumptions
that are subject to risks and uncertainties and are not guarantees of
future performance. Actual results could differ materially from those
contained in any forward-looking statement as a result of various
factors, including, without limitation: the risk that the conditions to
the closing of the private placement are not satisfied,unexpected costs,
charges or expenses that reduce cash runway; that Exicure's pre-clinical
programs do not advance into the clinic or result in approved products
on a timely or cost effective basis or at all; regulatory developments;
and the ability of Exicure to protect its intellectual property rights.
Exicure's pipeline programs are in various stages of pre-clinical and
clinical development, and the process by which such pre-clinical or
clinical therapeutic candidates could potentially lead to an approved
therapeutic is long and subject to significant risks and uncertainties.
Risks facing the Company and its programs are set forth in the Company's
filings with the SEC. Except as required by applicable law, the Company
undertakes no obligation to revise or update any forward-looking
statement, or to make any other forward-looking statements, whether as a
result of new information, future events or otherwise.

View Comments and Join the Discussion!